[
  {
    "ts": null,
    "headline": "US Equity Indexes Rise as Healthcare Jumps, October Rate-Cut Certainty Increases Amid Surprise Fall in Private Payrolls",
    "summary": "US equity indexes rose at the close on Wednesday amid gains in healthcare and increasing bets favori",
    "url": "https://finnhub.io/api/news?id=2773ac517cad9f7334b97c8ca3bc6e16ed94b3b558af0a0f32ccb9433f36b485",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759351970,
      "headline": "US Equity Indexes Rise as Healthcare Jumps, October Rate-Cut Certainty Increases Amid Surprise Fall in Private Payrolls",
      "id": 136952242,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "US equity indexes rose at the close on Wednesday amid gains in healthcare and increasing bets favori",
      "url": "https://finnhub.io/api/news?id=2773ac517cad9f7334b97c8ca3bc6e16ed94b3b558af0a0f32ccb9433f36b485"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare Helps Lift US Equity Indexes After Federal Shutdown Begins",
    "summary": "US equity indexes rose ahead of the close on Wednesday amid strong gains in the healthcare sector an",
    "url": "https://finnhub.io/api/news?id=26f967bc0e65373ca871110fb9a6f5a71e2f2cb3b47c5951634e8317d6bd24b4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759348643,
      "headline": "Healthcare Helps Lift US Equity Indexes After Federal Shutdown Begins",
      "id": 136952244,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "US equity indexes rose ahead of the close on Wednesday amid strong gains in the healthcare sector an",
      "url": "https://finnhub.io/api/news?id=26f967bc0e65373ca871110fb9a6f5a71e2f2cb3b47c5951634e8317d6bd24b4"
    }
  },
  {
    "ts": null,
    "headline": "US Equity Indexes Mixed Amid Healthcare Gains While Treasury Yields Drop as Partial Shutdown Begins",
    "summary": "US equity indexes were mixed in midday trading on Wednesday as healthcare helped offset losses, whil",
    "url": "https://finnhub.io/api/news?id=61675de07f152141193b70daa10b4e4341d46e83bbed41139e9ff6a4533b822a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759340871,
      "headline": "US Equity Indexes Mixed Amid Healthcare Gains While Treasury Yields Drop as Partial Shutdown Begins",
      "id": 136952246,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "US equity indexes were mixed in midday trading on Wednesday as healthcare helped offset losses, whil",
      "url": "https://finnhub.io/api/news?id=61675de07f152141193b70daa10b4e4341d46e83bbed41139e9ff6a4533b822a"
    }
  },
  {
    "ts": null,
    "headline": "Iron Overload Syndrome Market Report 2025-2035, Profiles of Chiesi Group, Novartis, PHARMACOSMOS, Protagonist Therapeutics, Regeneron Pharmaceuticals",
    "summary": "Iron overload syndrome, including hereditary hemochromatosis, is a disorder marked by excessive iron buildup in the body, primarily due to HFE gene mutations or secondary causes like chronic transfusions. Early diagnosis using serum ferritin and genetic testing is crucial to prevent irreversible damage to organs like the liver and heart. Treatments such as therapeutic phlebotomy, iron chelation, and lifestyle changes effectively manage iron levels. The global market is growing due to improved di",
    "url": "https://finnhub.io/api/news?id=532392b9d4e1083adba74e135081280863720fbec18d59b448ddefca7859fba9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759311780,
      "headline": "Iron Overload Syndrome Market Report 2025-2035, Profiles of Chiesi Group, Novartis, PHARMACOSMOS, Protagonist Therapeutics, Regeneron Pharmaceuticals",
      "id": 136944451,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Iron overload syndrome, including hereditary hemochromatosis, is a disorder marked by excessive iron buildup in the body, primarily due to HFE gene mutations or secondary causes like chronic transfusions. Early diagnosis using serum ferritin and genetic testing is crucial to prevent irreversible damage to organs like the liver and heart. Treatments such as therapeutic phlebotomy, iron chelation, and lifestyle changes effectively manage iron levels. The global market is growing due to improved di",
      "url": "https://finnhub.io/api/news?id=532392b9d4e1083adba74e135081280863720fbec18d59b448ddefca7859fba9"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron’s Evkeeza Receives FDA Approval to Treat HoFH in Children Aged 1 to Less Than 5",
    "summary": "Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the best NASDAQ stocks to buy according to hedge funds. On September 26, Evkeeza (evinacumab-dgnb), an ANGPTL3 antibody developed by Regeneron Pharmaceuticals, received an extended indication approval from the US FDA for the treatment of children from age 1 to less than 5 years old with homozygous familial […]",
    "url": "https://finnhub.io/api/news?id=83906f34070b621c5929d6dcae966385c9a1a8c2f6c39bb7de23d4986097e433",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759299402,
      "headline": "Regeneron’s Evkeeza Receives FDA Approval to Treat HoFH in Children Aged 1 to Less Than 5",
      "id": 136944452,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the best NASDAQ stocks to buy according to hedge funds. On September 26, Evkeeza (evinacumab-dgnb), an ANGPTL3 antibody developed by Regeneron Pharmaceuticals, received an extended indication approval from the US FDA for the treatment of children from age 1 to less than 5 years old with homozygous familial […]",
      "url": "https://finnhub.io/api/news?id=83906f34070b621c5929d6dcae966385c9a1a8c2f6c39bb7de23d4986097e433"
    }
  }
]